Methods of diagnosing and treating autism
View Patent ↗The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR). The invention further provides methods of preventing or reducing the risk of a fetus or child developing an ASD by administering to the mother an agent that blocks the binding of maternal antibodies to the one or more fetal biomarkers listed above or by removing from the mother antibodies that bind to the one or more fetal biomarkers.
1. A method of determining a risk of a human offspring for developing an autism spectrum disorder (ASD) comprising detecting in a biological sample from the mother or potential mother of the offspring the presence of maternal antibodies that bind to one or more biomarkers selected from the group consisting of a lactate dehydrogenase (LDH) protein, a guanine deaminase (GDA) protein, a collapsin response mediator protein 1 (CRMP1) protein, a dihydropyrimidinase-like protein 2 (DPYSL2) protein, a stress-induced phosphoprotein 1 (STIP1) protein and a Y Box Binding Protein 1 (YBX1) protein, wherein said biological sample is selected from the group consisting of blood, serum, plasma, and saliva, and wherein the presence of maternal antibodies that bind to the one or more biomarkers indicates an increased risk of the offspring for developing an ASD.
2. The method of claim 1 , wherein the biological sample is selected from the group consisting of blood, serum, and plasma.
3. The method of claim 1 , wherein the presence of maternal antibodies that bind to one or more biomarkers selected from the group consisting of an LDH protein, a GDA protein, a CRMP1 protein and an STIP1 protein are detected.
4. The method of claim 1 , wherein the presence of maternal antibodies that bind to one or more biomarkers selected from the group consisting of an LDH protein, a CRMP1 protein and an STIP1 protein are detected.
5. The method of claim 1 , wherein the offspring is a neonate.
6. The method of claim 1 , wherein the offspring is a fetus.
7. The method of claim 1 , wherein said biological sample is obtained prior to conception and said detecting occurs prior to conception.
8. The method of claim 1 , wherein the mother or potential mother has a child with an ASD.
9. The method of claim 1 , wherein the mother or potential mother has a familial history of ASD or autoimmune disease.
10. The method of claim 1 , comprising detecting in the biological sample the presence of maternal antibodies that bind to the DPYSL2 protein.
11. The method of claim 1 , wherein the LDH protein is an LDH-A subunit and/or an LDH-B subunit.
12. The method of claim 1 , comprising detecting in the biological sample the presence of maternal antibodies that bind to the GDA protein.
13. The method of claim 1 , wherein the method comprises contacting the sample with one or more synthetic or recombinant polypeptides selected from the group consisting of a synthetic or recombinant polypeptide comprising an amino acid sequence of a lactate dehydrogenase (LDH), a guanine deaminase (GDA), a collapsin response mediator protein 1 (CRMP1), a stress-induced phosphoprotein 1 (STIP1), and a Y Box Binding Protein 1 (YBX1).
14. The method of claim 13 , wherein the one or more synthetic or recombinant polypeptides are attached to a solid support.
15. The method of claim 13 , wherein the maternal antibodies are detected by Western blot, dot blot, ELISA, radioimmunoassay, immunoprecipitation, electrochemiluminescence, immunofluorescence, or multiplex bead assay.
16. The method of claim 13 , wherein the maternal antibodies are detected by a detectable signal selected from the group consisting of fluorescence, chemiluminesence, color, and radioactivity.
17. The method of claim 13 , wherein the maternal antibodies are detected by FACS analysis, scintillation proximity assay (SPA), FRET, or sandwich-type antibody assay.
18. The method of claim 10 , further comprising detecting in the biological sample the presence of maternal antibodies that bind to the YBX1 protein.
19. The method of claim 1 , wherein the presence of maternal antibodies that bind to one or more biomarkers selected from the group consisting of an LDH protein, a GDA protein and an STIP1 protein are detected.
20. The method of claim 1 , wherein the presence of maternal antibodies that bind to one or more biomarkers selected from the group consisting of a GDA protein, a CRMP1 protein and an STIP1 protein are detected.